Check-Cap Ltd.(CHEK)Earnings, Financials & Key Ratios
CHEK•NASDAQ
$1.86
Price updated Jun 20, 2026
AboutCheck-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation. The company was incorporated in 2004 and is based in Isfiya, Israel.Show more
- Revenue$0
- EBITDA-$26M-35.2%
- Net Income-$25M-43.2%
- EPS (Diluted)-4.30-43.3%
- ROE-226.19%-318.4%
CHEK Price & Volume
Check-Cap Ltd. (CHEK) stock price & volume — 10-year historical chart
Loading chart...
Check-Cap Faces Imminent Liquidity and Solvency Risks
Investment Thesis • Updated 2024Q4
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent Liquidity Exhaustion
Key Thesis Takeaways
- Check-Cap remains a pre-revenue entity with no commercial sales, leaving the firm without a viable path to operational sustainability.
- The company has experienced a catastrophic erosion of its financial foundation, with total assets collapsing from $49.5 million in 2022Q3 to just $377.0K by 2024Q4.
- Investors should exercise extreme caution as the firm faces severe liquidity constraints and potential cessation of operations due to a negative equity position of -$1.4 million.
Verdict Logic
the company's inability to generate revenue combined with a critical liquidity shortage, reflected in a current ratio of 0.15, suggests an extremely high risk of total capital loss.
CHEK Growth Metrics
Check-Cap Ltd. (CHEK) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-46.56%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-46.26%
Return on Capital
10 Years-108.79%
5 Years-101.02%
3 Years-111.57%
Last Year-233.22%
Peers Comparison
Key metrics vs top competitors for Check-Cap Ltd. (CHEK)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.86 | $10.88M | -0.43 | — | — | -226.19% | — | |
| $1.11 | $7.91M | -2.02 | 47901.74% | -131.27% | -34.42% | — | |
| $5.06 | $2.62B | -29.76 | 40.34% | -2.58% | -17.08% | — | |
| $7.24 | $90.45M | -28.96 | 14.52% | -9.05% | -70.95% | — | |
| $0.79 | $601.41K | -0.07 | — | — | -137.73% | — | |
| $148.70 | $8.7B | -45.34 | 32.33% | -34.34% | -26.46% | — |
Compare CHEK vs Peers
Check-Cap Ltd. (CHEK) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when CHEK posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CHEK Frequently Asked Questions
Check-Cap Ltd. (CHEK) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is CHEK profitable?
Check-Cap Ltd. (CHEK) reported a net loss of $25.1M for fiscal year 2024.
Dividend & Returns
What is CHEK's return on equity?
Check-Cap Ltd. (CHEK) has a return on equity (ROE) of -226.2%. Negative ROE indicates the company is unprofitable.
What is Check-Cap Ltd.'s free cash flow?
Check-Cap Ltd. (CHEK) had negative free cash flow of $0.0M in fiscal year 2024, likely due to heavy capital investments.